-
1 Differential susceptibility of HLA class II antigens induced by γ-interferon in human neuroblastoma cell lines．Cancer Res. 49：1824?1828, 1989
Sugimoto T., Horii Y., Hino T., Kemshead J.T., Kuroda H., Sawada T., Morioka H. Imanishi J. and Inoko H.
-
2 Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy．International Journal of Cancer, 47：732?737, 1991
Kuroda H., Sugimoto T., Ueda K., Tsuchida S., Horii Y., Inazawa J., Sato K. and Sawada T.
-
3 Long-term effects of mass screening for neuroblastoma in infancy．Am．J．Pediatr．Hemato1．0ncol. 13：3?7，1991
Sawada T., Matsumura T., Kawakatsu H., Sugimoto T., Kuroda H., Hosoi H., Michihata T., Saida T. and Hino T.
-
4 Physical mapping of the DDX1 gene to 340 kb 5' of MYCN. Oncogene. 13: 1561-1565，1996
Kuroda H., White P.S., Sulman E.P., Manohar C.F., Reiter J.L., Cohn S.L. and Brodeur G.M.
-
5 Frequent detection of TrkA expression in human neuroblastoma cell lines. Acta Paediatrica Japonica. 40 : 644-646, 1998
Horii Y., Kuroda H., and Sugimoto T.
-
6 Signal transduciotn pathway of TRK-B in human neuroblastoma cells. Jap. J. Cancer Res. 2001, 92: 152-160, 2001
Sugimoto T., Kuroda H., Moritake H., Hattori S., and Horii Y.
-
7 Signaling pathway of ciliary neurotrophic factor in neuroblastoma cell lines. Med. Pediatr. Oncol. 36:118-121, 2001
Kuroda H., Sugimoto T., Horii Y., and Sawada T.
-
8 Analysis of PTEN/MMAC1 alteration in neuroblastoma. Cancer Gen. Cytogen., 125: 151-155, 2001
Moritake H, Horii Y, Kuroda H and Sugimoto T.
-
9 Outocome of acute lymphoblastic leukemia in children with AL90 regimen: Impact of rresponse to treatment and sex difference on prognostic factors. Med. Ped. Oncology, 37:10-19, 2001
Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H, Kawakami K, Ayukawa H, Akiyoshi K, Kamizono J, Tamai Y, Kinukawa N and Okamura J.
-
10 Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene. Cancer Genet and Cytogenet, 135: 48-56, 2002
Moritake H., Sugimoto T., Asada Y., Yoshida M., Maehara Y., Epstein A. L. and Kuroda H.
-
11 Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplantation, December 1-2, 2003
Imashuku S., Teramura T., Morimoto A., Naya M. and Kuroda H.
-
12 Non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from a family donor based on fetomaternal microchimerism in pediatric hematologic malignancies. J Pediatr Hematol Oncol., 26: 68-71, 2004
Ishida H., Morimoto A., Yoshihara T., Kuroda H., Mori K., Fujii N., Tamura S., Hibi S., Todo S., Maruya E. and Imashuku S.
-
13 Treatment of Epstein-Barr virus-associated peripheral T-cell lymphoma. British Journal of Dermatology, 150:1038-1040, 2004
Imashuku S., Teramura T., Konishi K., Kikuchi S., Tamura S., Maeda Y. and Kuroda H.
-
14 Non-T-cell-depleted HLA haploidentical stem cell transplantation based on feto-maternal microchimerism in pediatric patients with advanced malignancies. Bone Marrow Transplant, 34: 373-375, 2004
Yoshihara T., Morimoto A., Inukai T., Kuroda H., Ishida H., Sugita K., Goi K., Imamura T., Todo S., Maruya E., Saji H., Nakazawa S. and Imashuku S.
-
15 Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin Cancer Res, 10:5940-5948, 2004
Kuwahara Y., Hosoi H., Osone S., Kita M., Iehara T., Kuroda H. and Sugimoto T.
-
16 Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16. Cancer Genetics and Cytogenetics, 158:172-179, 2005
Kuroda H., Moritake H., Sawada K., Kuwahara Y., Imoto I., Inazawa J. and Sugimoto T.
-
17 Successful non-T-cell-depleted HLA-haploidentical 3-loci mismatched bone marrow transplantation. Eur J Haematol, 74:529-532, 2005
Yagyu S., Kuroda H., Fujiki A., Tamura S., Iehara T., Morimoto A., Sugimoto T., Imashuku S.
-
18 Response to imatinib mesylate in a patient with cyclic eosinophil oscillations. Int J Hematology, 81:310-314, 2005
Imashuku S., Kakazu N., Ueda I., Morimoto A., Harada H., Teramura T., Fukushima-Nakase Y., Kuroda H.
-
19 Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol 23: 5205-5210, 2005
Gotoh T., Hosoi H., Iehara T., Kuwahara Y., Osone S., Tsuchiya K., Ohira M., Nakagawara A., Kuroda H. and Sugimoto T.
-
20 Infliximab for Pediatric Patients with Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Jpn J Pediatric Hematol, 20:16-21, 2006
Tamura S., Kuroda H., Maeda Y., Yagyu S., Nakai N., Ishida H., Yoshihara T., Morimoto A., Imashuku S.
-
21 Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. Int J Hematology, 85:246-255, 2007
Yoshihara T., Okada K., Kobayashi M., Kikuta A., Kato K., Adachi N., Kikuchi K., Ishida H., Hirota Y., Kuroda H., Nagatoshi Y., Inukai T., Koike K., Kigasawa H., Yagasaki H., Tokuda K., Kishimoto T., Nakano T., Fujita N., Goto H., Nakazawa Y., Kanegane H., Matsuzaki A., Osugi Y., Hasegawa D., Uoshima N., Nakamura K., Tsuchida M., Tanaka R., Watanabe A. and Yabe H.
-
22 Sensorineural hearing loss in a case of familiar hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 49(6):856-858, 2007
Imashuku S., Kohdera U., Teramura T., Ueda I., Morimoto A., Naya M., Kuroda H.
-
23 Late appearance of a Philadelphia chromosome in a patient with therapy-related acute myeloid leukemia and high expression of EVI1. Cancer Genetics and Cytogenetics 180: 115-120, 2008
Yagyu S., Morimoto A., Kakazu N., Tamura S., Fujiki A., Nakase Y., Iehara T., Hosoi H., and Kuroda H.
-
24 Trastuzumab activates allogeneic or autologous antibody-dependent cellular Cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the Cytotoxicity. Clin Cancer Res 14(4): 1192-1199, 2008
Katsumi Y., Kuwahara Y., Tamura S., Kikuchi K., Otabe O., Tsuchiya K., Iehara T., Kuroda H., Hosoi H. and Sugimoto T.
-
25 Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am. J. Hematol. 83:721-727, 2008
Sato E., Ohga S., Kuroda H., Yoshiba F., Nishimura M., Nagasawa M., Inoue M. and Kawa K.
-
26 Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: A novel diagnostic tool for therapy stratification of neuroblastoma. Cancer Letters 309: 185-189, 2011
Yagyu S., Iehara T., Gotoh T., Miyachi M., Katsumi Y., Kikuchi K., Tsuchiya K., Osone S., Kuroda H., Sugimoto T., Sawada T. and Hosoi H.
-
27 Allo-SCT in a patient with CRMCC with aplastic anemia using a reduced intensity conditioning regimen. Bone Marrow Transplant. 47(8): 1126-1127, 2012
Asai D., Osone S., Imamura T., Sakaguchi H., Nishio N., Kuroda H., Kojima S., Hosoi H.
-
28 Stem cell transplantation for paediatric patients with non-anaplastic peripheral T-cell lymphoma in Japan.Br J Haematol. 159(1):88-93, 2012
Kobayashi R., Fujita N., Mitsui T., Iwasaki F., Suzumiya J., Kuroda H., Nishimura R., Sasahara Y., Takeshita Y., Kato K., Okumura H., Sakamaki H., Yabe H., Kawa K., Kato K., Suzuki R.
-
29 A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines. Cancer Lett. 30;331(1):115-121, 2013
Sugimoto T., Gotoh T., Yagyu S., Kuroda H., Iehara T., Hosoi H., Ohta S., Ohira M., Nakagawara A.
-
30 Case reports of severe congenital neutropenia treated with unrelated cord blood transplantation with reduced-intensity conditioning. J Pediatr Hematol Oncol, 38(1): 49-52, 2016.
Osone S., Imamura T., Fukushima-Nakase Y., Kitamura-Masaki A., Kanai S., Imai T., Imashuku S., Kuroda H.
-
31 Allogeneic Hematopoietic Cell Transplantation for Dyskeratosis Congenita: A Report of 3 Cases. J Pediatr Hematol Oncol, 22: 2017.
Tamura S, Imamura T, Urata T, Kobayashi M, Gen M, Tomii T, Do J, Osone S, Ishida H, Hosoi H, Kuroda H.
